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Background: Due to lack of any curative therapy for ALS, symptomatic treatment and maintenance of quality of
life (QoL) is very important. We aimed to characterize the affected domains of QoL in ALS patients and to identify
factors which are associated with reduced QoL and increased depression.
Methods: 159 ALS patients answered standardized questionnaires (Beck Depression Inventory-II, SF-36 Health
Survey questionnaire, revised ALS functional rating scale). Multiple regression analysis was used to identify
correlations between clinical features of ALS patients and depression/QoL scores. In addition, QoL data from ALS
patients were compared to age-matched reference values representing the German normal population.
Results: QoL of ALS patients was reduced in nearly all SF-36-categories. Progression of physical impairment was
positively correlated with depression but reduced QoL scores only in items directly related to physical function.
However, QoL was considerably influenced by depression, independently from physical impairment. Regarding
distinct patient characteristics one of the most interesting findings was that increasing age was correlated with
significantly worse QoL results regarding social functioning.
Conclusions: Depressive symptoms had a strong influence on QoL, hence their detection and treatment is of
particular importance. Different domains of QoL are differently affected in subgroups of ALS patients. Being aware
of these differences can be valuable for both ALS professional and family caregivers and physicians.
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Amyotrophic lateral sclerosis (ALS) is the most common
motor neuron disease in adults. Degeneration of upper
and lower motor neurons leads to rapidly progressive
paralysis of skeletal muscles, thereby also affecting re-
spiratory, speech and swallowing functions. Therefore
ALS patients are confronted with progressive physical
impairment and loss of communication [1]. Despite in-
tensive research efforts, curative therapy is lacking so
far. Thus palliative care of patients suffering from this
incurable and terminal disease with the aim to alleviate
disease symptoms as much as possible is of high import-
ance. Clinical care and management has become a topic* Correspondence: Koerner.Sonja@mh-hannover.de
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unless otherwise stated.of increasing research interest [2–4]. Improvement of
quality of life (QoL) is most relevant as patients with
psychological distress have a greater risk of mortality [5].
Many studies have reported surprisingly good QoL in
ALS patients despite the dramatic and rapidly progres-
sive physical impairment [2–4, 6–8]. The interaction of
disability and depression respectively QoL in ALS has
been controversially discussed [2–4, 6, 7, 9, 10]. Does
physical disability automatically lead to development of
depression and reduced quality of life? Or are patients
able to adapt to the new situation and to replace activ-
ities no longer possible due to disease-related physical
impairment (profession, hobbies) by other similarly satis-
fying interests? And if the latter statement is true, does
it also apply to ALS patients where disability rapidly
deteriorates with disease progression and therefore con-
stantly requires new adjustments? Differential results ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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low sample sizes and to the use of different tools for as-
sessment of QoL and depressive symptoms. Moreover,
evaluation of these items is especially difficult in ALS
patients as they are restricted in many activities due to
disease-related physical limitations. Hence QoL in ALS
patients must be determined in different areas of life.
Until now, it is still unclear to what extent progressive
physical limitations are necessarily associated with in-
creasing depression and decreasing QoL and which
other factors are important.
In our study in a large cohort of 159 ALS patients we
intended to characterize the impact of several factors
(physical impairment, disease duration, gender, disease
onset and age) on depressive symptoms and QoL in ALS
patients and to specify the relationship between physical
impairment, depression and QoL. We further aimed to
elucidate which aspects of QoL are affected in ALS pa-
tients and whether there are differences related to the
disease phenotype. We aimed to provide more system-
atic and detailed evidence for the relevance of ALS-
related limitations in physical and social functions. This
knowledge should contribute to more specific therapy
and care, adjusted to the individual situation of a
patient.
Methods
One hundred fifty nine ALS patients from the ALS out-
patient clinic at Hannover Medical School participated
in the survey. The study has been approved by the
ethical committee of Hannover Medical School and all
subjects gave informed consent to the participation. The
study was performed in accordance with the Declaration
of Helsinki principles. All patients had met the revised
El Escorial criteria for probable or definite ALS [11] and
did not have clinical signs of frontotemporal dementia,
while specific tests to detect minor cognitive/fronto-
temporal abnormalities were not routinely performed.
Patients filled in three standardized questionnaires (Beck
Depression Inventory - II (BDI), SF-36 Health Survey
questionnaire (SF-36) and revised ALS Functional Rating
Scale (ALSFRS-R)).
The ALSFRS-R is a well-established and widely used
score for the functional status of patients with ALS. It is
based on 12 items, each rated on a 0–4 point scale. The
rate of functional disability ranges from 0 (maximum
disability) to 48 (normal) points. Three items of the
ALSFRS-R assess bulbar involvement (speech, salivation,
swallowing), which therefore can be rated from 0 (max-
imum bulbar involvement) to 12 (no bulbar involve-
ment) [12]. Further six items of the ALSFRS-R address
motor function of upper and lower limbs (handwriting,
cutting food, dressing and hygiene, walking, turning
in bed, climbing stairs). The last three items estimateinvolvement of respiratory function (dyspnoea, orthop-
noea, respiratory insufficiency).
The BDI is a 21-question multiple-choice self-report
inventory, commonly used for quantifying levels of de-
pression. Each of the 21 items is scored on a scale from
0 (symptom not present) to 3 (symptom very intense)
leading to an overall-range of 63. The cutoffs used are
0–8: no depressive symptoms, 9–13: minimal depressive
symptoms, 14–19: mild depressive symptoms, 20–28:
moderate depressive symptoms, 29–63 severe depressive
symptoms [13].
The SF-36 questionnaire is a multi-purpose, short-form
health survey with 36 questions. It is a self-administered
QoL scoring system that includes eight independent
scales: 1. Physical functioning (limitations in physical ac-
tivities), 2. Physical role (limitations in usual role activities
because of physical health problems), 3. Bodily pain, 4.
General health perception, 5. Vitality (energy and fatigue),
6. Social functioning (limitations in social activities be-
cause of physical or emotional problems), 7. Emotional
role (limitations in usual role activities because of emo-
tional problems), 8. Mental health (psychological distress
and well-being) [14]. Each of the question responses relate
to a different pre-coded numeric value. The sums of the
questions in their section form raw scores for each of the
eight scales. The raw scores are translated into one from 0
to 100, with 0 representing a very low level of QoL in that
item and 100 representing a very positive response. The
SF–36 was chosen as it is short, easy to complete and
covers areas that appear appropriate to patients with ALS,
such as ability to perform work and daily activities, phys-
ical functioning and social functioning. The questionnaire
is widely used and has undergone a substantial amount of
testing for reliability, validity and responsiveness; it has
further been proven to be an adequate instrument for
ALS patients [15, 16].
The SF-36 was standardized in a German norm popu-
lation (n = 2914) [17]. Age-specific reference values gen-
erated in this population have already been applied in
other studies for comparison of QoL of patients with dif-
ferent diseases [18, 19] and were also used in the present
study to compare QoL of ALS patients with the German
general population. If the reference value was outside
the 95 % confidence interval regarding the ALS study
population, we concluded a significant difference.
The ALS patient group was characterized regarding
gender, onset, age, disease duration and disease severity
(see Table 1). For variables with an asymptotic normal
distribution mean and standard deviation (SD) are re-
ported, for variables without asymptotic normal distribu-
tion median, minimum and maximum are reported in
addition. To identify correlations between disease severity,
age and disease duration with the extent of depression
(BDI) and different aspects of QoL (SF-36), we used linear
Table 1 Characteristics of the ALS patient cohort
Characteristics of patient cohort ALS patients
Gender (male : female), n = 159 92: 67 (58 % : 42 %)
Onset (spinal : bulbar), n = 155 113: 42 (73 % : 27 %)
Age, n = 159
mean (SD) 60.7 years (SD 11.1)
Disease duration, n = 145
mean (SD) 40.2 months (SD 43.1)
median (min - max) 24 months (1 – 234)
ALSFRS-R, n = 155
mean (SD) 28.46 (SD 10.9)
ALSFRS-R bulbar, n = 155
mean (SD) 7.68 (SD 3.8)
median (min - max) 9 (0–12)
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised
SD: standard deviation
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sion analysis. Afterwards all variables which tended to sig-
nificance (p-value < 0.2) were included in a multiple
regression model. In a last step we used backward selec-
tion (with p > 0.05 as exclusion criterion) to determine the
final model. All results including regression coefficent ß,
confidence interval for ß and p-values for each of these
calculations are listed in Additional file 1: Table S1. A
summary of the results is provided in Table 3. Statistical
analyses were performed using SPSS V. 19 (SPSS, Chicago,
IL) software, a p-value of <0.05 was considered significant.
Results
We analysed data from 159 ALS patients (92 male and
67 female) with a mean age of 60.69 years (standard de-
viation of 11.12 years) and a median disease duration of
24 months (range: 1 month to 19.5 years). Further char-
acteristics of the cohort are listed in Table 1.
As revealed by BDI scores, depressive symptoms were
frequent in ALS. Using the regular BDI score, 30 % of
the patients suffered from moderate or severe depressive
symptoms (Table 2). Since the BDI is often criticized for
overestimating depression in physically handicapped per-
sons because of its somatic items, we also calculated the
prevalence of depression after removal of the somatic
items (regarding ability to work, sleep, exhaustion, ap-
petite, weight loss and concern about health) in new
approximate ranges. This analysis showed indeed a lower
prevalence in the category “mild depressive symptoms”,
while the frequency of moderate or severe depressive
symptoms was still 25 % (Table 2).
Compared to the German general population in age-
matched groups, QoL was significantly reduced in our
ALS patient cohort in all categories represented by the
SF-36 subscales except for the item “Bodily pain” whereALS patients only marginally differed from the general
population. Differences related to “mental health” seemed
to be only relevant in older patients (older than 51 years)
(Fig. 1).
Linear regression analysis was performed to identify im-
pact factors on depression and QoL. The results of the final
model after backward selection are displayed in Table 3.
(All results including the results of the simple regression
models are summarized in Additional file 1: Table S1).
Advanced physical impairment (lower ALSFRS-R) was
correlated with increasing depression (higher BDI scores)
(Fig. 2). The multiple regression analysis showed that the
extent of physical impairment also had an independent
impact on the QoL (SF-36) scales related to physical func-
tioning and vitality, regardless of the severity of depres-
sion, while the other six categories were not affected
(Table 3). The level of depression, on the other hand, inde-
pendent of the ALSFRS-R score, significantly influenced
the majority of QoL categories, including general health,
vitality, social functioning, emotional role and mental
health (Table 3). That was also the case when we used the
BDI score without somatic items, except for the QoL cat-
egories physical role and bodily pain (Additional file 2:
Table S2).
Patients with a lower ALSFRS-R bulbar score had sig-
nificantly less bodily pain. Pain in ALS is typically caused
by muscle atrophy and subsequent increase in sensitivity
of bones and joints, limited mobility as well as muscle
cramps and spasticity [20]. Patients with predominant
bulbar involvement are to a lesser extent restricted in
their motility and therefore probably suffer less from
pain due to immobility. As, on the other hand, patients
with spinal onset develop weakness and atrophy of limb
muscles as initial symptoms, they had significantly worse
QoL scores in the categories “physical functioning and
role” (Table 3).
Higher age was correlated with lower SF-36 scores
regarding social functioning (Table 3).
Gender had no influence on depression or QoL.
Surprisingly, disease duration had no influence on
depression and QoL either, although longer disease
duration was correlated with lower ALSFRS-R scores
(p < 0.01) and similar correlations as for the ALSFRS-R
could have been expected.
Discussion
Quality of life in ALS patients – comparison with general
population-derived reference values
In our study, QoL was significantly reduced in ALS pa-
tients compared to reference values from the general
population [17] in nearly all subscales. This reduction of
QoL in ALS patients has been described before in one
study which also used the SF-36 questionnaire [15].
Other studies, however, resulted in contrary results: a
Table 2 Association of different patient characteristics with depression (BDI) and quality of life (SF-36) scores
BDI Physical functioning Physical role Bodily pain General health Vitality Social functioning Emotional role Mental health
ALSFRS-R ↓ ↑ (p < 0.001) ↓ (p < 0.001) 0.092 - 0.731 ↓ (p < 0.01) 0.175 0.774 0.052
ALSFRS-R bulbar ↓ 0.345 - - ↑ (p < 0.01) - 0.116 0.864 - 0.555
Disease duration - - - 0.113 - - - - -
Gender - - - - - - - - -
Onset - Sig. ↓ for spinal onset
(p < 0.01)
Sig. ↓ for spinal onset
(p < 0.001)
0.743 - - - - -
Age ↑ 0.126 0.072 - - 0.058 - ↓ (p < 0.05) - 0.292
BDI ↑ n.a. 0.132 ↓ (p < 0.001) ↓ (p < 0.05) ↓ (p < 0.001) ↓ (p < 0.001) ↓ (p < 0.001) ↓ (p < 0.001) ↓ (p < 0.001)
-: p-value >0.2 in the simple regression, variable not included in the final multiple regression model
n.a.: not applicable
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised












Table 3 Prevalence of different degrees of depression according to the BDI scores
Degree of depression BDI complete (range 0–63) BDI without somatic items (range 0–45)
Range Prevalence (%) Range Prevalence (%)
No depressive symptoms BDI 0-8 19 % BDI 0-5 30 %
Minimal depressive symptoms BDI 9-13 24 % BDI 6-9 29 %
Mild depressive symptoms BDI 14-19 26 % BDI 10-13 16 %
Moderate depressive symptoms BDI 20-28 19 % BDI 14-20 18 %
Severe depressive symptoms BDI 29-63 12 % BDI 21-45 7 %
BDI: Beck Depression Inventory
Körner et al. BMC Neurology  (2015) 15:84 Page 5 of 8direct comparison of ALS patients with healthy control
persons revealed no differences in QoL [4]; in a study by
Kübler et al., 80 % of ALS patients rated their QoL as
satisfactory or good [2]. QoL includes many domains of
experience which are differently affected in ALS and dif-
ferently rated by ALS patients. One explanation for these
controversial results might be the differential emphasis
of different tools to assess QoL. There is an ongoing dis-
cussion whether so called health related questionnaires
as the SF-36 are generally suitable in ALS patients. They
are often criticized for focusing mainly on functional sta-
tus and not being able to accurately reflect the patients’
individual QoL [21–23]. Those studies suggest to ra-
ther use more individualized questionnaires as e.g., the
SEIQoL-DW (Schedule for the Evaluation of Individual
Quality of Life Direct Weight) which allows patients to
focus on fields of their life which they consider relevant
and which are not influenced by physical impairment.
These questionnaires indeed highlight QoL more from the
patients’ perspective. But they also have disadvantages: In
our clinical experience, patients always name areas and
activities they can still perform without difficulties, which
results in relatively high QoL scores. These tests therefore
demonstrate that ALS patients are able to shift their prior-
ities and thereby maintain their QoL to a certain degree.
We think, however, that they are at risk of overlookingFig. 1 Comparison of quality of life (QoL) in ALS patients to age-group spe
declined in ALS patients in nearly every scale. Limitations in the field “men
“bodily pain” QoL of ALS patients barely differs from the general populatio
and “Emotional Role” a normal distribution cannot be assumed the compa
31–40 years 5 patients, 41–50 years 22 patients, 51–60 years 53 patients, 61categories of QoL which are affected in ALS patients. One
could therefore wrongly assume that there is nothing to
improve in the symptomatic treatment/care of ALS pa-
tients. General health status questionnaires such as the
SF-36, on the other hand, separately assess physical, men-
tal, social and emotional factors. They have the disadvan-
tage that some subscales depend on physical abilities
which we clearly accept as a limitation of our study. How-
ever, in our analysis, ALS patients rated their QoL worse
not only in the physical categories but also in nearly all
other dimensions. There are already few studies which
used several questionnaires from both categories [21–23].
Nevertheless further research is required. It would be
interesting to combine different questionnaires with ob-
jective and subjective assessment of QoL, using disease-
specific and more general questionnaires in large ALS
populations, to give the most comprehensive estimation
of well-being of ALS patients.
In fact, in the present study the most obvious difference
in QoL between ALS patients and general population was
observed regarding the physical domains (physical func-
tioning and physical role). This result was to be expected
but should not be considered unchangeable. In our expe-
rience, patients often hesitate to use walking frames or
wheel chairs and rather accept immobility which appar-
ently has a considerable negative impact on QoL. Basedcific reference values of the German general population. QoL is
tal health” only become apparent in older patients, and in the subscale
n. As in the scales “Physical Functioning”, “Physical Role”, “Bodily Pain”
rison in these fields can only be rated descriptive. Sample sizes:
–70 years 42 patients, >70 years 37 patients
Fig. 2 Linear regression analysis showed a significant negative correlation between ALSFRS-R and BDI. Advanced physical impairment (lower ALSFRS-R)
was correlated with increasing depression (higher BDI scores)
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maximum improvement in the physical domain by use of
assistive technologies. Higher autonomy and mobility
might subsequently even improve QoL in other categories,
namely regarding social functioning which was also sig-
nificantly reduced in ALS patients. An early prescription
of assistive technologies by the treating neurologist or
family practitioner as well as sufficient guidance by
physical therapists and medical supply stores seems
to be essential. Future studies will be necessary to
specifically analyse the effect of early and compre-
hensive equipment with assistive devices capable to
improve mobility and communication on QoL of ALS
patients.
The scores in the category “bodily pain” were similar
in the ALS cohort compared to the reference values, as
opposed to all other SF-36 scales. A prevalence of pain
in ALS patients up to 50 % has been described [24]. In
another study which specifically addressed this issue, the
median physical pain score reported by ALS patients
was 2 on a six point scale, but 20 % of patients rated
their pain as ≥4 [25], indicating that even though pain
was not a common problem in our ALS cohort, a subset
of ALS patients does suffer from severe pain.
Factors associated with higher levels of depression and
decreased quality of life in ALS patients
Severity of depressive symptoms in our cohort was posi-
tively correlated to the extent of physical impairment.
This has been controversially described in previousstudies: Some authors support a relationship between
depression and disease stage [2, 9, 10, 26] while
others do not [4, 27]. However, one must differentiate
between advanced physical impairment (i.e., deterior-
ation of ALSFRS-R) and just longer disease duration.
Despite progressive physical impairment during disease
duration and a positive correlation between the severity of
depression and physical impairment, there was no signifi-
cant correlation between depression and disease duration
in our cohort. This finding is in line with a previous study
which found even a negative correlation between depres-
sive symptoms and time since diagnosis [2]. With longer
disease duration patients can develop strategies to cope
with the diagnosis and the physical impairment; hence de-
pressive symptoms are less frequent or at least not pro-
gressive with longer disease duration despite increasing
disability.
According to the literature, physical impairment does
not influence QoL [4, 7, 23, 28]. We found that in fact
physical impairment (i.e., low ALSFRS-R scores) only
had a significant impact on the physical functioning and
vitality scale of the SF-36 but did not influence other
aspects. Severity of depression as measured by BDI, on
the contrary, had a substantial impact on QoL on several
scales including general health, vitality, mental health as
well as social and emotional well-being. This impact was
not modified by the extent of physical impairment. Our
results are in line with the literature as it has been
described previously that depression and QoL are highly
negatively related [29]. In ALS patients, fatigue and
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poor QoL [23, 30, 31].
Data on prevalence of depression in ALS in differ-
ent studies depend on the tests they used, but there
is some evidence that depressive symptoms are frequent
[2, 26, 30, 32–34]. In the present study over 30 % of
patients had moderate or severe depressive symptoms. Al-
though the BDI as well as other depression scores include
somatic markers of depression and therefore can over-
estimate the prevalence of depression in ALS patients
[8, 20, 35–37], it has been used in ALS patients and a high
reliability of the BDI in assessing self-reported depressive
symptoms has been shown [10, 38]. Moreover, the preva-
lence of moderate or severe depressive symptoms in our
ALS population was only slightly lower when we removed
the somatic items from the BDI. Hence a significant pro-
portion of ALS patients seem to suffer from depression. It
can neither be recommended to use the BDI as a depres-
sion screening instrument nor to treat ALS patients with
antidepressants based on their BDI score. One must, how-
ever, be aware of the frequency of depressive symptoms in
ALS patients and pharmacological treatment as well as
psychological support should be made available if neces-
sary. The significant correlation between depression and
QoL clearly suggests that efficient treatment of depression
could contribute to improve QoL. Depressive symptoms
should therefore not be accepted as an inevitable conse-
quence of an incurable disease [38].
Regarding QoL in elderly ALS patients, we observed a
significant negative correlation of age with the domain
social functioning. This means that increasing age maybe
is another factor which adds to the limitation of social
contacts. Health professionals as well as family members
should have that in mind and specifically address this
issue in older ALS patients.
Conclusion
Our study answers the questions raised in the background
sections as follows: QoL was considerably reduced in ALS
patients, especially regarding (but not restricted to) phys-
ical domains. Physical impairment promotes depressive
symptoms but does not necessarily lead to reduced QoL.
However, depressive symptoms are frequently observed in
ALS and can have a serious negative effect on QoL. Iden-
tification of other potentially treatable factors which pro-
mote development of depression in ALS patients could
therefore be useful.
One can conclude that, despite the lack of curative
therapy, ALS carers (including specialized physicians as
well as nursing and familial caregivers) can substantially
contribute to maintenance of QoL at the highest possible
level. QoL and depressive symptoms should be regularly
evaluated and special requirements of patients with dif-
ferent ALS phenotypes should be kept in mind.Recommendations
1. Advanced physical impairment was correlated with
higher degrees of depression. Hence, assistive
devices for improved mobility and autonomy should
be provided by clinicians specialized in ALS and
sound instructions by physical therapists should
ensure proper use by patients.
2. QoL was much more influenced by depression than
by physical impairment. Timely diagnosis and
pharmacological treatment of depressive symptoms
is therefore crucial in ALS and could improve QoL.
3. Low-threshold psychotherapeutic support should be
available for ALS patients.
4. In elderly patients, health professionals and family
caregivers should particularly focus on social
functioning as reduction in QoL in this category
is age-dependent.
5. Implementation of point 1–4 requires involvement
of neurologists specialized in ALS, qualified
physical therapists and instructors in medical
supply stores, psychiatrists and/or psychotherapists
as well as sensitive professional or familial nursing
staff, thereby highlighting the importance of
a multidisciplinary team for the treatment of
ALS-patients.
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